HealthTech Bioactives (HTBA) has partnered with Abolis Biotechnologies to develop strains that produce valuable polyphenols, addressing supply chain challenges and driving innovation in the industry.
The partnership aims to secure production, increase capacities, and reduce manufacturing costs by developing high-value molecules with limited sourcing availability. The companies will work together to add up to eight more molecules to the development pipeline.
“We are thrilled to contribute to HTBA growth through this strategic collaboration,” said Cyrille Pauthenier, co-founder and CEO of Abolis. “Abolis has a proven track record in microbial strain development for these products, and HTBA brings deep market knowledge worldwide. This partnership is a perfect match between our complementary expertise.”
The partnership marks a significant step forward in the development of sustainable, bio-based production methods for high-value polyphenols, ultimately benefiting consumers and driving growth in the health sector.
